In various malignancies, such as BLCA, an abnormal increase in CDKs (including CDK2/4/6) and cyclins (including Cyclin D1/E1) and a decrease in CDK inhibitors (including p16/21/27) are common 32-37. This evidence concerns the gene CDK2 and bladder transitional cell carcinoma.